Sickle Cell Disease Clinical Trial
Official title:
An Open-Label 12-Week Food Study to Assess the Safety, Tolerability, And Physiological Effects of An Amino Acid Food Product, AXA4010, In Subjects With Sickle Cell Disease.
Verified date | January 2021 |
Source | Axcella Health, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label study to understand the safety and tolerability of AXA4010, a novel composition of amino acids in adult and adolescent subjects with sickle cell disease over 12 weeks. The study also assesses the effects of this amino acid composition on the structure and function of the vascular system. Physiological effects on structure and function will be assessed by Magnetic Resonance Imaging (MRI) to assess blood flow in the brain and kidneys and the 6-Minute walk with pulse oximetry. Changes in blood biomarkers of inflammation will also be assessed.
Status | Completed |
Enrollment | 9 |
Est. completion date | January 11, 2021 |
Est. primary completion date | January 11, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Willing to participate in the study and provide written informed consent - Male and female adolescent (ages 12 to 17 inclusive) and adult (= 18 years of age) subjects with a prior medically documented diagnosis of sickle cell disease (SS or ß0 thalassemia) - For Cohort 2 adult subjects only, a Screening cerebral blood flow/ velocity by transcranial doppler (TCD) should be >110 cm/sec - Subjects must show active hemolysis at the time of screening based on each of the following parameters: - Lactate dehydrogenase (LDH) = 2x above upper limits of normal (ULN) of the age- and gender-appropriate ranges - Indirect bilirubin > 2x of the age- and gender-appropriate ULN - Absolute reticulocyte counts > 2x of the age- and gender-appropriate ULN - Able to ambulate (without assistance or walkers etc.) in a 6- minute walk test Exclusion Criteria: - Ten (10) or more Vascular-Occlusive Crisis (VOC)s that required hospital or emergency room (ER) visits within the past 12 months - Any clinically significant changes abnormalities on the screening 12-lead ECG - Estimated glomerular filtration rate <60mL/min/1.73m2 appropriately corrected - Hemoglobin (Hb) =6.0 g/dL at Screening - Subjects on chronic transfusion regimens, or who received a transfusion within the last 2 months prior to screening - Experienced VOC or any other sickle crises (eg acute chest syndrome, splenic sequestration, dactylitis, stroke) within the last 2 months prior to Screening - Current or history of significant alcohol consumption - Other poorly controlled medical conditions as judged by the Investigator - Known sensitivity and/or history of clinically significant food intolerance/allergies to proteins (including whey, soy, casein, amino acids, etc.) - Unable or unwilling to adhere to contraception requirements - Any contraindications to an MRI scan for Cohort 2 only - Any other condition that, in the opinion of the Investigator, renders the subject at risk for compliance, compromises the well-being of the subject, or hinders study completion |
Country | Name | City | State |
---|---|---|---|
United States | Primary Care research | Atlanta | Georgia |
United States | Foundation for Sickle Cell Disease Research | Hollywood | Florida |
United States | Advanced Pharma CR, LLC | Miami | Florida |
United States | Newark Beth Israel Medical Center | Newark | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Axcella Health, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Study Product-Emergent Adverse Events [Safety and Tolerability ] | Incidence of study product emergent adverse events (AEs) and serious adverse events (SAEs) | Baseline to Week 12 | |
Secondary | Change in Lactate Dehydrogenase (LDH) | Baseline to Week 12 | ||
Secondary | Change Indirect Bilirubin | Baseline to Week 12 | ||
Secondary | Change Absolute Reticulocyte Count | Baseline to Week 12 | ||
Secondary | Changes in Renal and Cerebral blood flow via MRI (in Adult Cohort 2 Only) | Baseline to Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A |